MicroVention Announces Settlement Against Former Employees for Trade Secret Misappropriation and Breach of Contract Among Other Claims
2024年7月16日 - 10:00PM
ビジネスワイヤ(英語)
Former Employees Include David Ferrera,
Nguyen (“Jake”) Le and Michelle Tran
MicroVention, a fully owned subsidiary of Terumo Corporation,
announced today that the United States District Court for the
Central District of California has issued an injunction permanently
enjoining defendants David Ferrera, Nguyen (“Jake”) Le and Michelle
Tran, former employees of MicroVention (“defendants”), from using,
disclosing, or possessing any MicroVention trade secret information
or confidential information and requiring that they undergo certain
trade secret remediation protocols to remedy the harm to
MicroVention.
MicroVention sued the defendants for Trade Secret
Misappropriation and Breach of Contract among other claims in 2020
related to defendants’ unlawful misappropriation of MicroVention’s
trade secrets related to its embolic coils system, access catheters
and guidewires used to treat aneurysms. In addition to the
permanent injunction, the Court rendered a Consent Judgment noting
that when Ferrera, Le and Tran left their employment with
MicroVention they violated their obligations and agreements of
confidentiality by taking with them significant amounts of
MicroVention files relating to MicroVention’s products and
business, and that Ferrera misappropriated MicroVention’s trade
secrets. The Court concluded that MicroVention is entitled to
recover from defendants a substantial monetary payment, as
reflected in a separate settlement agreement. The Court also
entered sanctions orders against some of the defendants related to
spoliation of evidence.
“At MicroVention, we hold the principles of innovation,
integrity, and respect for intellectual property in the highest
regard. Our recent legal actions are a testament to our unwavering
commitment to protect our own intellectual property rights.
However, our dedication extends beyond the confines of our own
interests; we actively advocate for the respect of intellectual
property rights throughout the industry,” said Carsten Schroeder,
President and CEO of MicroVention. “This commitment to ethical
business practices and intellectual property protection is
foundational to fostering a fair and competitive market. It ensures
that groundbreaking medical technologies continue to evolve and
reach those in need, underpinning our mission to be an industry
leader in the creation and commercialization of innovative
neuroendovascular technologies that provide a meaningful
improvement in patient lives.”
The case is MicroVention, Inc. v. Balt, Inc. et al., Case
8:20-cv-02400-JLS-KES, in the United States District Court for the
Central District of California.
About MicroVention, Inc.
Founded in 1997, MicroVention develops and markets medical
devices that enable or significantly improve treatment of
cerebrovascular diseases. In 2006, Terumo Corporation, a major
worldwide medical device company headquartered in Tokyo, Japan,
acquired MicroVention into their family of Companies. Terumo’s
acquisition of MicroVention allowed both Companies to leverage
their unique, proprietary technologies toward an increased focus on
treating cerebrovascular diseases. Headquartered in California,
MicroVention products are today sold in more than seventy countries
through a direct sales organization alongside strategic
distribution partnerships. Manufacturing facilities are in Aliso
Viejo, California and San José, Costa Rica. For more information on
MicroVention, please visit www.microvention.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and
has been committed to "Contributing to Society through Healthcare"
for 100 years. Based in Tokyo and operating globally, Terumo
employs more than 30,000 Associates worldwide to provide innovative
medical solutions in more than 160 countries and regions. The
company started as a Japanese thermometer manufacturer and has been
supporting healthcare ever since. Now, its extensive business
portfolio ranges from vascular intervention and cardio-surgical
solutions, blood transfusion and cell therapy technology, to
medical products essential for daily clinical practice. Terumo will
further strive to be of value to patients, medical professionals,
and society at large. For more information on Terumo, please visit
www.terumo.com/about/profile.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240716647059/en/
MicroVention Media Contact:
Christine McCullough Global Corporate Communications MicroVention,
Inc. + 1 714 206 9800 christine.mccullough@microvention.com